Recombinant Human Osteoprotegerin/OPG/TNFRSF11B (C-His)
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 50 µg |
| Content : | Lyophilized from a 0.2 um filtered solution of PBS, pH7.4 |
| AA sequence : | Recombinant Human Osteoprotegerin is produced by Human 293 Cells. The target gene encoding E22-L401 is expressed with a 8His tag at the C-terminus. |
| Alternative Name : | Tumor Necrosis Factor Receptor Superfamily Member 11B; Osteoclastogenesis InhibitoryFactor; Osteoprotegerin; TNFRSF11B; OCIF; OPG |
Source : Human 293 Cells;
Osteoprotegerin (OPG) is a secreted homodimer protein that belongs to tumor necrosis factor receptor superfamily. OPG is highly expressed in fetal kidney, liver and lung. It is up-regulated by increasing calcium-concentration in the medium and estrogens and down-regulated by glucocorticoids. OPG can have multiple effects on TNFSF10 and TNFSF11. As a decoy receptor for TNFSF11/RANKL, OPG neutralizes its function in osteoclastogenesis. OPG also inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Osteoprotegerin (OPG) is a secreted homodimer protein that belongs to tumor necrosis factor receptor superfamily. OPG is highly expressed in fetal kidney, liver and lung. It is up-regulated by increasing calcium-concentration in the medium and estrogens and down-regulated by glucocorticoids. OPG can have multiple effects on TNFSF10 and TNFSF11. As a decoy receptor for TNFSF11/RANKL, OPG neutralizes its function in osteoclastogenesis. OPG also inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
